[0011] In a sixth aspect, there is provided a crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid L-arginine salt (Compound A L-arginine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 20.8, 21.8, and 25.4 °2θ ± 0.2 °2θ.

[0012] In a seventh aspect, there is provided a crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid L-lysine salt (Compound A L-lysine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 19.8, 20.7, and 21.2 °2θ ± 0.2 °2θ.

[0013] In an eighth aspect, there is provided a crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid ethanolamine salt (Compound A ethanolamine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 21.8, 22.7, and 27.1 °2θ ± 0.2 °2θ.

[0014] In a ninth aspect, there is provided a crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid diethanolamine salt (Compound A diethanolamine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 16.9, 23.7, and 25.0 °2θ ± 0.2 °2θ.

[0015] In a tenth aspect, there is provided a crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid tromethamine salt (Compound A tromethamine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 10.1, 14.2, and 21.1 °2θ ± 0.2 °2θ.

[0016] In an ~~eleventh aspect~~embodiment, there is provided an amorphous [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (amorphous Compound A).

[0017] In an embodiment~~twelfth~~ aspect, there is provided a substantially amorphous [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid potassium salt (Compound A potassium salt).

[0018] Still another embodiment provided is directed to a pharmaceutical composition comprising a crystalline or amorphous form of Compound A, or a salt thereof, and a pharmaceutically acceptable excipient.

[0018a] In an eleventh~~thirteenth~~ aspect, there is provided a pharmaceutical composition comprising a compound selected from the group consisting of: Compound A Form A as defined above, Compound A Form B as defined above, Compound A Form C as defined above, Compound A Form D as defined above, Compound A sodium salt as defined above, Compound A L-arginine salt as defined above, Compound A L-lysine salt as defined above, Compound A ethanolamine salt as defined above, Compound A diethanolamine salt as defined above, Compound A tromethamine salt as defined above, ~~amorphous Compound A as defined above, and Compound A potassium salt as defined above,~~ and a pharmaceutically acceptable excipient.

[0019] Additionally, the disclosure provides in one embodiment a method for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by hypoxia inducible factor (HIF). The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A, Compound A Form B, Compound A Form C, Compound A Form D, Compound A sodium salt, Compound A L-arginine salt, Compound A L-lysine salt, Compound A ethanolamine salt, Compound A diethanolamine salt, Compound A tromethamine salt, amorphous Compound A, and Compound A potassium salt, as described generally above.

[0020] Also provided is a method for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by erythropoietin (EPO), comprising administering to a patient in need thereof, a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A, Compound A Form B, Compound A Form C, Compound A Form D, Compound A sodium salt, Compound A L-arginine salt, Compound A L-lysine salt, Compound A ethanolamine salt, Compound A diethanolamine salt, Compound A tromethamine salt, amorphous Compound A, and Compound A potassium salt, as described generally above.

[0021] Also provided is a method for treating, pretreating, or delaying onset or progression of anemia, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A, Compound A Form B, Compound A Form C, Compound A Form D, Compound A sodium salt, Compound A L-arginine salt,

Compound A L-arginine salt, Compound A L-lysine salt, Compound A ethanolamine salt, Compound A diethanolamine salt, Compound A tromethamine salt, amorphous Compound A, and Compound A potassium salt, as described generally above.

[0022a] In a ~~fourteenth~~ twelfth aspect, there is provided the use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A as defined above, Compound A Form B as defined above, Compound A Form C as defined above, Compound A Form D as defined above, Compound A sodium salt as defined above, Compound A L-arginine salt as defined above, Compound A L-lysine salt as defined above, Compound A ethanolamine salt as defined above, Compound A diethanolamine salt as defined above, and Compound A tromethamine salt as defined above, ~~amorphous Compound A as defined above, and Compound A potassium salt as defined above,~~ for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by hypoxia inducible factor (HIF).

[0022b] In a ~~fifteenth~~ thirteenth aspect, there is provided the use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A as defined above, Compound A Form B as defined above, Compound A Form C as defined above, Compound A Form D as defined above, Compound A sodium salt as defined above, Compound A L-arginine salt as defined above, Compound A L-lysine salt as defined above, Compound A ethanolamine salt as defined above, Compound A diethanolamine salt as defined above, and Compound A tromethamine salt as defined above, ~~amorphous Compound A as defined above, and Compound A potassium salt as defined above,~~ for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by erythropoietin (EPO).

[0022c] In a ~~sixteenth~~ fourteenth aspect, there is provided the use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A as defined above, Compound A Form B as defined above, Compound A Form C as defined above, Compound A Form D as defined above, Compound A sodium salt as defined above, Compound A L-arginine salt as defined above, Compound A L-lysine salt as defined above, Compound A ethanolamine salt as defined above, Compound A diethanolamine salt as defined above, and Compound A tromethamine salt as defined above, ~~amorphous Compound A as defined above, and Compound A potassium salt as defined above,~~ for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of anemia.

44. Compound A diethanolamine salt according to claim 41, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 150 °C.

45. Compound A diethanolamine salt according to claim 44, wherein the DSC curve is substantially as shown in Figure 18.

46. Crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid tromethamine salt (Compound A tromethamine salt) characterized by an X-ray powder diffractogram comprising the following peaks: 10.1, 14.2, and 21.1 °2θ ± 0.2 °2θ.

47. Compound A tromethamine salt according to claim 46, wherein the diffractogram further comprises peaks at 20.1, 25.7, and 28.4 °2θ ± 0.2 °2θ.

48. Compound A tromethamine salt according to claim 46, wherein the diffractogram is substantially as shown in Figure 19.

49. Compound A tromethamine salt according to claim 46, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 176 °C.

50. Compound A tromethamine salt according to claim 49, wherein the DSC curve is substantially as shown in Figure 20.

~~51. Amorphous [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (amorphous Compound A).~~

~~52. Substantially amorphous [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid potassium salt (Compound A potassium salt).~~

~~53. Compound A potassium salt according to claim 52, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 291 °C.~~

~~54. Compound A potassium salt according to claim 53, wherein the DSC curve is substantially as shown in Figure 22.~~

~~55~~51. A pharmaceutical composition comprising a compound selected from the group consisting of: Compound A Form A according to claim 1, Compound A Form B according to

claim 6, Compound A Form C according to claim 11, Compound A Form D according to claim 16, Compound A sodium salt according to claim 21, Compound A L-arginine salt according to claim 26, Compound A L-lysine salt according to claim 31, Compound A ethanolamine salt according to claim 36, Compound A diethanolamine salt according to claim 41, Compound A tromethamine salt according to claim 46, ~~amorphous Compound A according to claim 51, and Compound A potassium salt according to claim 52,~~ and a pharmaceutically acceptable excipient.

~~56~~52. The pharmaceutical composition of claim ~~55~~51, comprising Compound A in Form A.

~~57~~53. The pharmaceutical composition of claim ~~56~~52, wherein at least about 85% of Compound A is in Form A.

~~58~~54. The pharmaceutical composition of claim ~~56~~52, wherein at least about 90% of Compound A is in Form A.

~~59~~55. The pharmaceutical composition of claim ~~56~~52, wherein at least about 95% of Compound A is in Form A.

~~60~~56. The pharmaceutical composition of claim ~~56~~52, wherein at least about 99% of Compound A is in Form A.

~~61~~57. The pharmaceutical composition of claim ~~56~~52, wherein at least about 99.5% of Compound A is in Form A.

~~62~~58. The pharmaceutical composition of claim ~~56~~52, wherein at least about 99.9% of Compound A is in Form A.

~~63~~59. The pharmaceutical composition of claim ~~56~~52, wherein at least about 99.99% of Compound A is in Form A.

~~64~~60. Use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A according to claim 1, Compound A Form B according to claim 6, Compound A Form C according to claim 11, Compound A Form D according to claim

16, Compound A sodium salt according to claim 21, Compound A L-arginine salt according to claim 26, Compound A L-lysine salt according to claim 31, Compound A ethanolamine salt according to claim 36, Compound A diethanolamine salt according to claim 41, and Compound A tromethamine salt according to claim 46~~, amorphous Compound A according to claim 51, and Compound A potassium salt according to claim 52~~, for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by hypoxia inducible factor (HIF).

~~65~~61. The use of claim ~~64~~60, wherein the condition mediated at least in part by HIF is tissue damage associated with ischemia or hypoxia.

~~66~~62. The use of claim ~~65~~61, wherein the ischemia is associated with an acute event selected from the group consisting of myocardial infarction, pulmonary embolism, intestinal infarction, chronic kidney failure, ischemic stroke, and renal ischemic-reperfusion injury.

~~67~~63. The use of claim ~~65~~61, wherein the ischemia is associated with a chronic event selected from the group consisting of cardiac cirrhosis, transient ischemic attack, macular degeneration, peripheral artery disease, and congestive heart failure.

~~68~~64. Use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A according to claim 1, Compound A Form B according to claim 6, Compound A Form C according to claim 11, Compound A Form D according to claim 16, Compound A sodium salt according to claim 21, Compound A L-arginine salt according to claim 26, Compound A L-lysine salt according to claim 31, Compound A ethanolamine salt according to claim 36, Compound A diethanolamine salt according to claim 41, and Compound A tromethamine salt according to claim 46~~, amorphous Compound A according to claim 51, and Compound A potassium salt according to claim 52~~, for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of a condition mediated at least in part by erythropoietin (EPO).

~~69~~65. Use of a therapeutically effective amount of a compound selected from the group consisting of: Compound A Form A according to claim 1, Compound A Form B according to claim 6, Compound A Form C according to claim 11, Compound A Form D according to claim 16, Compound A sodium salt according to claim 21,

Compound A L-arginine salt according to claim 26, Compound A L-lysine salt according to claim 31, Compound A ethanolamine salt according to claim 36, Compound A diethanolamine salt according to claim 41, and Compound A tromethamine salt according to claim 46~~, amorphous Compound A according to claim 51, and Compound A potassium salt according to claim 52~~, for the manufacture of a medicament for treating, pretreating, or delaying onset or progression of anemia.

~~70~~66. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein the compound used in the method is Compound A Form A.

~~71~~67. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 85% of the compound used in the method is Compound A Form A.

~~72~~68. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 90% of the compound used in the method is Compound A Form A.

~~73~~69. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 95% of the compound used in the method is Compound A Form A.

~~74~~70. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 99% of the compound used in the method is Compound A Form A.

~~75~~71. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 99.5% of the compound used in the method is Compound A Form A.

~~76~~72. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 99.9% of the compound used in the method is Compound A Form A.

~~77~~73. The use of claim ~~64~~60, ~~68-64~~ or ~~69~~65, wherein at least about 99.99% of the compound is Compound A Form A.